Amyotrophic Lateral Sclerosis clinical trials

Explore recruiting amyotrophic lateral sclerosis clinical trials.

Recruiting amyotrophic lateral sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Amyotrophic Lateral Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

Germany, Italy, Norway, Ireland, Sweden, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Sweden, Germany, Italy, Spain, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

Germany, Czechia, Poland, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)

Sweden, France, Germany, Denmark, Italy, Poland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS

Latvia

Human Pharmacology (Phase I)- Other EU CTIS Study details

Amyotrophic Lateral Sclerosis trials by city

Amyotrophic Lateral Sclerosis in Toronto Amyotrophic Lateral Sclerosis in Vancouver Amyotrophic Lateral Sclerosis in Montreal Amyotrophic Lateral Sclerosis in Calgary Amyotrophic Lateral Sclerosis in Edmonton Amyotrophic Lateral Sclerosis in Ottawa Amyotrophic Lateral Sclerosis in Winnipeg Amyotrophic Lateral Sclerosis in Quebec City Amyotrophic Lateral Sclerosis in Hamilton Amyotrophic Lateral Sclerosis in Kitchener Amyotrophic Lateral Sclerosis in London Amyotrophic Lateral Sclerosis in Halifax Amyotrophic Lateral Sclerosis in New York Amyotrophic Lateral Sclerosis in Los Angeles Amyotrophic Lateral Sclerosis in Chicago Amyotrophic Lateral Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease